DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 022260
» See Plans and Pricing
The generic ingredient in VELETRI is epoprostenol sodium. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the epoprostenol sodium profile page.
Summary for 022260
Tradename: | VELETRI |
Applicant: | Actelion Pharms Ltd |
Ingredient: | epoprostenol sodium |
Patents: | 2 |
Formulation / Manufacturing: | see details |
Pharmacology for NDA: 022260
Physiological Effect | Vasodilation |
Medical Subject Heading (MeSH) Categories for 022260
Suppliers and Packaging for NDA: 022260
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
VELETRI | epoprostenol sodium | INJECTABLE;INJECTION | 022260 | NDA | Actelion Pharmaceuticals US, Inc. | 66215-402 | 66215-402-01 | 1 VIAL in 1 CARTON (66215-402-01) > 10 mL in 1 VIAL |
VELETRI | epoprostenol sodium | INJECTABLE;INJECTION | 022260 | NDA | Actelion Pharmaceuticals US, Inc. | 66215-403 | 66215-403-01 | 1 VIAL in 1 CARTON (66215-403-01) > 10 mL in 1 VIAL |
Paragraph IV (Patent) Challenges for 022260
Tradename | Dosage | Ingredient | NDA | Submissiondate |
---|---|---|---|---|
VELETRI | INJECTABLE;INJECTION | epoprostenol sodium | 022260 | 2017-03-31 |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1.5MG BASE/VIAL | ||||
Approval Date: | Jun 27, 2008 | TE: | RLD: | Yes | |||||
Patent: | Start Trial | Patent Expiration: | Mar 15, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | Start Trial | Patent Expiration: | Feb 2, 2027 | Product Flag? | Substance Flag? | Delist Request? |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 0.5MG BASE/VIAL | ||||
Approval Date: | Jun 28, 2012 | TE: | RLD: | Yes | |||||
Patent: | Start Trial | Patent Expiration: | Mar 15, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription